Protective effect of amlodipine on rat bone tissue after orchidectomy.
OBJECTIVE
Our study aimed to investigate the effect of amlodipine on bone metabolism in orchidectomized rats.


METHODS
Eight-week-old rats were divided into three groups. The sham-operated control group (SHAM) and the control group after orchidectomy (ORX) received the standard laboratory diet (SLD). The experimental group after orchidectomy (ORX+AML) received SLD enriched with amlodipine for 12 weeks. Bone marker concentrations in serum of PINP, OPG and IGF-1, and the levels of CTX-I, BAP and BMP-2 in a bone homogenate were measured using enzyme-linked immunosorbent assay. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry. The femurs were used for biomechanical testing.


RESULTS
Bone markers (CTX-I, BAP, BMP-2) in ORX were higher versus SHAM. In ORX+AML there was a decrease in PINP, CTX-I, BAP, BMP-2 and OPG versus ORX. IGF-1 was decreased in ORX versus SHAM. In ORX+AML it was increased versus ORX. In ORX, a decrease was demonstrated versus SHAM in BMD of the whole body, in the lumbar vertebrae and in both femurs. In ORX+AML there was an increase in BMD of the whole body versus ORX. Three-point bending test revealed a decrease in maximal load values in ORX versus SHAM. After amlodipine administration there was an increase in the left femur versus ORX.


CONCLUSIONS
Amlodipine is capable of mitigating the negative effects of orchidectomy and could be a good prevention of osteoporosis.
Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Kralove, Czech Republic. gradosovai@ lfhk.cuni.cz
Iveta
I
Gradosova
Helena
H
Zivna
Vladimir
V
Palicka
Sona
S
Hubena
Klara
K
Svejkovska
Pavel
P
Zivny
D000469:Alkaline Phosphatase / Q000378:metabolism; D017311:Amlodipine / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001696:Biomechanical Phenomena / Q000502:physiology; D015519:Bone Density / Q000187:drug effects; D055396:Bone Morphogenetic Protein 2 / Q000378:metabolism; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D024042:Collagen Type I / Q000378:metabolism; D004195:Disease Models, Animal; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects*; D010024:Osteoporosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D053244:Osteoprotegerin / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D051381:Rats; D017208:Rats, Wistar
D015415:Biomarkers; D055396:Bone Morphogenetic Protein 2; D002121:Calcium Channel Blockers; D024042:Collagen Type I; D053244:Osteoprotegerin; D010446:Peptide Fragments; D011347:Procollagen; C047202:procollagen Type I N-terminal peptide; D017311:Amlodipine; D007334:Insulin-Like Growth Factor I; D000469:Alkaline Phosphatase